The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | J | Antiinfectives for systemic use | |
| 2 | J07 | Vaccines | |
| 3 | J07B | Viral vaccines | |
| 4 | J07BA | Encephalitis vaccines |
| Code | Title | |
|---|---|---|
| J07BA01 | Encephalitis, tick borne, inactivated, whole virus | |
| J07BA02 | Encephalitis, Japanese, inactivated, whole virus | |
| J07BA03 |
| Active Ingredient | Description | |
|---|---|---|
| Encephalitis, tick borne |
Encephalitis, tick borne suspension for injection is indicated for the active (prophylactic) immunization of persons of 16 years of age and older against tick-borne encephalitis (TBE). Its pharmacodynamic effect consists of the induction of a sufficiently high concentration of anti-TBE antibody to provide protection against the TBE virus. |
|
| Japanese encephalitis, live attenuated |
Japanese encephalitis is a disease caused by the mosquito-borne Japanese encephalitis virus (JEV). Japanese Encephalitis Vaccine acts by inducing antibodies that neutralize live JEV. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| IXIARO Japanese Encephalitis Vaccine | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| TICOVAC Suspension for injection in a pre-filled syringe | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
